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Abstract
Introduction: Interleukin-34 (IL-34) is a recently defined cytokine, showing a functional overlap with macrophage
colony stimulating factor (M-CSF). This study was undertaken to address the expression of IL-34 in rheumatoid
arthritis (RA) patients and to investigate its regulation and pathogenic role in RA.
Methods: IL-34 levels were determined in the RA synovium, synovial fluid (SF) and fibroblast-like synovial cells
(FLS) by immunohistochemistry, real-time PCR, enzyme-linked immunosorbent assay and immunoblotting. RA
activity was assessed using Disease Activity Score 28 (DAS28) activity in the plasma collected at baseline and one
year after treatment. Conditioned media (CM) were prepared from RA FLS culture with tumor necrosis factor alpha
(TNFa) for 24 hours and used for functional assay.
Results: IL-34 was expressed in the synovium, SF, and FLS from RA patients. The production of IL-34 in FLS was
up-regulated by TNFa in RA samples compared with osteoarthritis (OA) patients. Importantly, the preferential
induction of IL-34 rather than M-CSF by TNFa in RAFLS was mediated by the transcription factor nuclear factor
kappa B (NF-B) and activation of c-Jun N-terminal kinase (JNK). IL-34 elevation in plasma from RA patients was
decreased after the administration of disease-modifying anti-rheumatic drugs (DMARDs) in accordance with a
decrease in DAS28. CM from RAFLS cultured with TNFa promoted chemotactic migration of human peripheral
blood mononuclear cells (PBMCs) and subsequent osteoclast (OC) formation, effects that were attenuated by an
anti-IL-34 antibody.
Conclusions: These data provide novel information about the production of IL-34 in RA FLS and indicate that IL-
34 is an additional osteoclastogenic factor regulated by TNFa in RA, suggesting a discrete role of IL-34 in
inflammatory RA diseases.
Introduction
Rheumatoid arthritis (RA) is an autoimmune chronic
inflammatory disease characterized by bone and carti-
lage destruction that is mediated by bone-resorbing
osteoclasts (OCs) [1,2]. OCs differentiate from the
monocyte/macrophage lineage of hematopoietic myeloid
progenitors in response to macrophage colony-stimulat-
ing factor (M-CSF) and RANKL (receptor activator of
NF-B ligand) [3,4] and participate in a variety of
inflammatory bone degenerative diseases. OC differen-
tiation correlates with the severity of the inflammatory
condition [2]. OCs mediate erosive bone resorption at
the bone-pannus interface of the synovium in RA joints
resulting from chronic inflammation of multiple synovial
joints [5]. Synovial fluid (SF) produced by the inflamed
synovium in joints, hyperplasic synovial fibroblasts, and
activated synovial T cells increases the production of
RANKL and several inflammatory cytokines [6,7]. These
inflammatory conditions lead to enhanced OC forma-
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Tumor necrosis factor alpha (TNFa) is well estab-
lished as a critical OC differentiation-enhancing factor
that acts by mediating mobilization of osteoclast precur-
sors (OCPs) from bone marrow into the inflamed joint,
where they appear to contribute to inflammatory erosive
arthritis [8]. TNFa-stimulated fibroblast-like synovial
cells (FLS) increase cytokine production [6], which
accelerates OC formation in the inflamed synovium of
RA [9]. Thus, the administration of TNFa blocking
agents results in a decrease in the pathological changes
indicative of RA inflammatory responses, and as such
provides a potential clinical benefit [10]. Recent studies
have shown that administration of an antibody (Ab)
against the M-CSF receptor, c-Fms or inhibitor, selec-
tively and completely blocks osteoclastogenesis and
bone erosion induced by TNFa injection or inflamma-
tory arthritis [11,12], suggesting a link between TNFa
and c-Fms under pathological inflammatory conditions.
Accordingly, identifying factors involved in TNFa-
induced OCPs mobilization and subsequent differentia-
tion that contribute to erosive arthritis is a matter of
considerable interest.
The recently discovered cytokine IL-34 binds to the
M-CSF receptor c-Fms [13]. The functional similarity of
IL-34 and M-CSF is demonstrated by their role in
osteoclastogenesis [14-18]. Although IL-34 and M-CSF
share the c-Fms receptor, their signal transduction
mechanisms and biological activity are not identical
[16]. Functional overlap [16], but differential expression,
of M-CSF and IL-34 has been observed in the context
of M-CSF receptor-mediated regulation of myeloid cells
[18]. However, whether IL-34 is involved in RA patho-
genesis is still unknown.
Materials and methods
Patients and reagents
All RA patients enrolled in this study fulfilled the 1987
revised criteria of the American College of Rheumatol-
ogy [19]. Patients were compared with age- and sex-
matched control patients with OA.
Informed consent was obtained from all patients and
the experimental protocol was approved by the Human
Research Ethics Committee of the University of Ulsan
College of Medicine (2010-871). SF was collected from
the knee joint (with or without swelling) of each patient
by sterile aspiration and centrifuged at 250g for 10 min-
utes. Cell-free RA synovial fluid (RA SF) was stored at
-70°C until used. Synovia were isolated from seven
patients with RA (mean age, 59.9 ± 12.3; range, 42 to 75
years) and seven patients with OA (mean age, 62.5 ±
8.2; range, 46 to 77 years). All patients were undergoing
knee replacement surgery. For the one-year follow-up
study, sera were collected from the patients listed in
Additional file 1 at baseline and one year after treatment
from ten patients with RA. RA activity was simulta-
neously assessed using Disease Activity Score 28
(DAS28) activity [20].
Pyrrolidine dithiocarbamate (PDTC), SP600125,
SB203580, PD98059, and anti-b-actin antibody was pur-
chased from Sigma (St. Louis, MO, USA). Rabbit anti-
human IL-34 for immunoblotting was from ProSci
Incorporated (Poway, CA, USA). Mouse anti-human IL-
34 for blocking IL-34 activity, mouse polyclonal immu-
noglobulin G (IgG), IL-17, TNFa, and IL-1b were pur-
chased from R&D Systems (Minneapolis, MN, USA).
Recombinant M-CSF, RANKL, and IL-34 were pur-
chased from PeproTech, Inc. (Rocky Hill, NJ, USA).
Immunohistochemistry
OA and RA synovia for immunohistochemistry analysis
were collected in accordance with experimental proto-
cols approved by the Stanford University Institutional
Review Board and with the patients’ informed consent
as described [12]. Sections of optimal cutting tempera-
ture (OCT) compound-embedded synovial tissue sam-
ples were cut on a cryostat (Thermo Scientific,
Kalamazoo, MI, USA) and fixed in 4% paraformaldehyde
for 10 minutes at 4°C. The slides were then washed
twice (5 minutes each) with PBS and permeabilized with
0.1% Triton X-100 for 3 minutes at room temperature.
After washing with PBS, endogenous peroxidase activity
was quenched with 0.03% H2O2 solution. The slides
were blocked with 7.5% normal goat serum for 20 min-
utes and thereafter incubated with 4 μg/ml of IL-34
antibody (LSBio, Seattle, WA, USA) or control rabbit
IgG (Abcam, Cambridge, MA, USA) for 20 minutes at
room temperature. Following two washes with PBS, the
slides were incubated with 1:200 diluted biotinylated
secondary antibody (Vectastain EliteABC Kit; Vector
Laboratories, Orton Southgate, Peterborough, UK) for
30 minutes. After washing with PBS, the slides were
incubated with complexed avidin-biotin horseradish per-
oxidase ABC reagent (Vectastain Elite ABCkit; Vector)
for 30 minutes, and then exposed to 3,3-diaminobenzi-
dine (DAB) substrate according to the manufacturer’s
instructions (Vector). The nuclei were subsequently
counterstained with hematoxylin (Vector). Tissues were
examined and photographed with an Olympus BX51
microscope outfitted with an Olympus DP72 digital
camera (Olympus).
Isolation of FLS and OCPs from human peripheral blood
mononuclear cells (PBMCs)
FLS were isolated by enzymatic digestion of synovial tis-
sues obtained from RA and OA patients undergoing
total joint replacement surgery, as previously described
[21]. Blood was collected from healthy volunteers and
PBMCs were obtained from whole blood by
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centrifugation over Ficoll gradients (Pharmacia Biotech,
Uppsala, Sweden) at 400g for 30 minutes and erythro-
cytes were removed by lysing in ACK buffer (0.15 M
NH4Cl, 1 mM KHCO3 and 0.1 mM EDTA, pH 7.2).
Conventional reverse transcriptase-polymerase chain
reaction (RT-PCR) PCR and quantitative real-time RT-PCR
Total RNA was extracted from synovial tissues obtained
from three RA patients, as indicated, using the RNeasy
Mini Kit (QIAGEN, Hilden, Germany). cDNA was
synthesized from total RNA using murine Moloney leu-
kemia virus reverse transcriptase (MMTV-RT, Gibco
BRL, Gaithersburg, MD, USA). The cDNA was ampli-
fied using the Takara PCR amplification kit (Takara Bio-
technology, Shiga, Japan); PCR was carried out in a
Perkin Elmer thermal cycler. Quantitative RT-PCR
(qRT-PCR) was performed using Power SYBR Green 1-
Step Kit and an ABI 7000 Real Time PCR System
(Applied Biosystems, Carlsbad, CA, USA) according to
the manufacturer’s instructions. The sequences of pri-
mers used were as follows: IL-34, 5’-TAC AGG AGC
CGA CTT CAG-3’ (sense) and 5’-CTC ACC AAG ACC
CAC AGA-3’ (antisense); M-CSF, 5’-GCT GCT TCA
CCA AGG ATT ATG-3’ (sense) and 5’- GGG TCA
CTG CTA GGG ATG-3’ (antisense); and GAPDH (gly-
ceraldehyde 3-phosphate dehydrogenase), 5’-AGC CAC
ATC GCT CAG ACA-3’ (sense) and 5’-GCC CAA TAC
GAC CAA ATC C-3’ (antisense). Results are expressed
as the ratio of target PCR product relative to GAPDH
product. The amplification protocol consisted of an
initial reverse transcription step at 48°C for 30 minutes,
followed by 40 cycles of denaturation at 95°C for 15 sec-
onds and annealing and extension at 60°C for 1 minute.
Enzyme-linked immunosorbent assay (ELISA)
IL-34 concentration was measured using an IL-34-specific
sandwich ELISA (R&D systems, Minneapolis, MN, USA)
in accordance with the protocols of the manufacturer.
Recombinant human IL-34 serially diluted in culture
media was used as a standard. ELISA plates were incu-
bated with mouse anti-human IL-34 Ab and then blocked
with 3% BSA in PBS for 1 hour at room temperature. SF
from patients with RA and OA, or supernatants from FLS
cultures were added to the plates. After washing with PBS
containing 0.05% Tween 20, each well was incubated with
biotinylated mouse anti-human IL-34 (0.5 μg/ml) for 2
hours at room temperature. Plates were then washed with
PBS containing 0.05% Tween 20 and incubated with strep-
tavidin conjugated to horseradish peroxidase (HRP) for 1
hour at room temperature. A color reaction was developed
with tetramethylbenzidine solution, and then stopped with
0.1 M H2SO4. The absorbance at 450 nm was measured
using a Bio-Rad microtiter plate reader (Bio-Rad Labora-
tories, Hercules, CA, USA).
Immunoblotting
RA FLS were collected and proteins were resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis and transferred to nitrocellulose paper (GE Health-
care, Piscataway, NJ, USA). The membranes were
immunoblotted with an anti-human IL-34 rabbit poly-
clonal IgG or b-actin antibody. Bound antibodies were
visualized with HRP-conjugated antibodies against rabbit
or mouse IgG using an enhanced chemiluminescence
Western blotting system (Millipore, Billerica, MA, USA).
PBMCs migration assay
Transmigration assays were performed as follows using
PBMCs: conditioned media (CM) was prepared by col-
lecting supernatant from RA FLS cultured in the pre-
sence of TNFa (10 ng/ml) for 24 hours. CM from RA
FLS cultures, recombinant IL-34 (100 ng/ml), or CM
plus anti-IL-34 Ab was added to the lower compart-
ments of a 5-μm pore Transwell system (Costar, Corn-
ing, NY, USA). PBMCs (1.2 × 106) were added to the
upper chamber of each transwell and allowed to migrate
for 6 hours. The number of PBMCs in the lower cham-
ber was then counted.
OC differentiation
For osteoclastogenesis, PBMCs were plated on 48-well
plates and cultured in a-MEM supplemented with 10%
fetal bovine serum (FBS) and cultured with RANKL
(100 ng/ml) plus M-CSF (100 ng/ml) as a control as
described [21] or RANKL (100 ng/ml) plus IL-34 (100
ng/ml). RANKL was added at a final concentration of
100 ng/ml to CM obtained from RA FLS cultured in the
presence of TNFa (10 ng/ml) for 24 hours. Osteoclastic
differentiation was maintained for 12 to 14 days prior to
tartrate resistant acid phosphatase (TRAP) staining and
scoring of multinucleated OCs, as previously described
[22].
Statistical analysis
Means ± standard deviations (SDs) were calculated for
all conditions, and differences between means were ana-
lyzed using Student’s t-test. A P-value < 0.05 was con-
sidered significant. Patient data were tested by the
Mann-Whitnney U test.
Results
High levels of IL-34 in synovia and SF from patients with
RA
To demonstrate the involvement of IL-34 in RA patho-
genesis, we first determined whether synovia and SF
from patients with RA (RA SF) displayed high levels of
IL-34. IL-34 mRNA expression was detected in synovia
obtained from three RA patients at levels similar to
those of M-CSF (Figure 1A); high levels of IL-34 mRNA
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(Figure 1A) and protein (Figure 1B) were observed in
human RA synovium compared to OA synovium. The
levels of IL-34 protein in RA SF were comparable to
those of M-CSF (Figure 1C). In addition, we found that
IL-34 protein was expressed in FLS from RA patients
(Figure 1D). These observations indicate that IL-34 is
expressed in synovial tissue, synovial fluid, and FLS
from RA patients, suggesting that IL-34 is an additional
factor involved in the pathogenesis of RA.
TNFa-induced IL-34 production by FLS of RA patients
FLS act as the main cell mediating the cytokine-rich envir-
onment of the inflamed synovium in RA pathogenesis [23]
and stimulate OC differentiation and activity in the
inflammatory bone destruction by regulating RANKL
expression [24,25]. Interestingly, we found that the level of
soluble IL-34 in RA SF from inflamed RA synovium (351.7
± 30.7 pg/ml) with joint swelling was significantly higher
than that in RA SF from non-inflamed RA synovium (81.1
± 24.5 pg/ml; P < 0.01) (Figure 2A). We therefore deter-
mined whether RA FLS produced IL-34 in response to
pro-inflammatory cytokines. RA FLS (n = 9) or OA FLS (n
= 4), used as a disease control, were cultured with TNFa,
IL-1b, or IL-17 (each at 10 ng/ml) for 24 hours. Interest-
ingly, the increase in IL-34 concentration was more
marked in TNFa-stimulated RA FLS than in IL-1b- or IL-
Figure 1 Expression of interleukin-34 (IL-34) in human rheumatoid arthritis (RA) synovium and synovial fluid (SF). (A) IL-34 and
macrophage colony-stimulating factor (M-CSF) mRNA levels in synovia from patients with RA (n = 3) and osteoarthritis (OA) (n = 3) were
determined by reverse transcriptase PCR (RT-PCR). Synovium were homogenized and lysed, and total RNA was extracted as described in
Materials and Methods. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA levels were detected as a control. (B) Representative
immunohistochemical images of OA or RA synovia stained with antibodies against IL-34 or isotype controls. Images are shown at 200× (upper)
and 400× (lower) magnification. Scale bars = 100 μm. (C) Synovial fluid (SF) from RA patients (n = 7) (RA SF) was collected and the
concentrations of M-CSF and IL-34 were measured using an enzyme-linked immunosorbent assay (ELISA) assay. (D) Expression of IL-34 protein in
fibroblast-like synovial cells (FLS) from RA patients (n = 6) was determined by immunoblotting against human IL-34. Whole-cell lysates of RA FLS
cells were resolved by SDS-PAGE and followed by immunoblotting with anti-human IL-34 and anti-b-actin antibodies.
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17-stimulated RA FLS (Figure 2B). In contrast, OA FLS
showed no significant changes in those responses (Figure
2B). Moreover, an analysis of IL-34 mRNA levels using
quantitative real-time RT-PCR showed that IL-34 mRNA
expression was markedly increased in TNFa-stimulated
RA FLS compared to controls (P < 0.01) (Figure 2C). IL-
1b and IL-17 treatment induced a smaller increase in IL-
34 mRNA expression (Figure 2C). However, the level of
IL-34 expression in control OA FLS was not significantly
modulated by these cytokines (Figure 2C). These results
provide the first demonstration that RA FLS produce IL-
34 and that this production is enhanced by TNFa.
Differential induction of IL-34 by RA FLS treated with
TNFa
IL-34 and M-CSF were recently reported to share the
same receptor, c-Fms [13]. Our data showed that IL-34
expression was enhanced after treatment with TNFa
Figure 2), suggesting that differential production of IL-
34, regulated by the pathological condition of RA, can
replace M-CSF function. To test this possibility, we next
examined whether TNFa differentially regulates IL-34
and M-CSF expression. RA FLS constitutively expressed
and produced both M-CSF and IL-34 (Figure 3A).
TNFa treatment caused a 12-fold increase in IL-34
mRNA expression above this basal level (Figure 3A,
right), but had little effect on M-CSF mRNA expression
(Figure 3A, left). Together, the level of IL-34 protein in
RA FLS was much greater than M-CSF production in
the presence of TNFa (Figure 3B), showing approxi-
mately a 1.5-fold increase in TNFa-treated RA FLS over
that of the control RA FLS (Figure 3C). Thus, these data
demonstrate the differential regulation of IL-34 and M-
CSF expression by TNFa.
TNFa activates NF-B and JNK, which are important
for TNFa-mediated gene expression and are involved in
the activation of FLS [26]. To understand better the
mechanism by which TNFa increases IL-34 production
in RA FLS, we examined the effects of inhibitors of NF-
B or JNK on IL-34 expression. RA FLS were pretreated
with the vehicle, NF-B inhibitor, PDTC, or the JNK
inhibitor, SP600125, at a concentration of 10 μM for 30
minutes followed by incubation with TNFa for 24 hours.
As shown in Figure 3D, the NF-B inhibitor, PDTC,
effectively reduced TNFa-induced IL-34 mRNA expres-
sion; moreover, JNK inhibition modestly decreased the
TNFa-induced elevation of IL-34. However, p38 or
extracellular signal-regulated protein kinase (ERK) inhibi-
tion did not affect TNFa-induced IL-34 mRNA expres-
sion (Figure 3D). Collectively, these results suggest that
the TNFa-induced increase in IL-34 expression in RA
FLS is mediated by NF-B and JNK pathways.
Clinical determination of IL-34 in plasma from patients
with RA
Given that IL-34 is up-regulated in inflamed synovium
and in RA FLS in response to TNFa, (Figure 2) the
levels of IL-34 may reflect the pathogenesis of
Figure 2 Effect of tumor necrosis factor alpha (TNFa) on the expression of interleukin-34 (IL-34) in rheumatoid arthritis (RA) and
osteoarthritis (OA) fibroblast-like synovial cells (FLS). (A) Paired samples of non-inflamed (n = 7) and inflamed (n = 7) synovial fluid (SF)
from individual RA patients were collected and analyzed for IL-34 by an enzyme-linked immunosorbent assay (ELISA). Closed triangles indicate
individual data points; horizontal bars show group means (P < 0.01, inflamed versus non-inflamed RA SF samples). (B) Fibroblast-like synovial
cells (FLS) were prepared and cultured as described in Materials and Methods. RA FLS (n = 9) and OA FLS (n = 7) were cultured with different
cytokines (10 ng/ml of TNFa, IL-1b, or IL-17) for 24 hours, and the concentration of IL-34 in the media was measured by ELISA. Closed squares
or circles indicate individual RA or OA data points, respectively; horizontal bars show group means (P < 0.01, IL-34 concentration in RA versus OA
after TNFa treatment). (C) OA and RA FLS were treated with different cytokines (10 ng/ml of TNFa, IL-1b, or IL-17) for 24 hours. IL-34 mRNA
levels in cell lysates were determined by quantitative reverse transcriptase-PCR (qRT-PCR). The relative expression of IL-34 mRNA was obtained
using the cycle threshold (Ct) method after normalization to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Data are presented as fold-
change of gene expression compared to untreated controls. Bars indicate the mean and SD of IL-34 mRNA expression relative to that of GAPDH
(*P < 0.05, N.S., not significant, compared to none treated).
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inflammation in RA patients. To explore this correla-
tion, we performed a comparative analysis of plasma IL-
34 levels in RA patients (n = 10) using ELISAs. The
patients with RA had higher plasma IL-34 levels than
normal or OA controls (Figure 4A). One group of
patients with rheumatoid arthritis, defined by a plasma
DAS28 score at baseline of 2.9 to 7.4, had undergone a
1-year follow-up treatment with DMARDs, including
methotrexate, sulfasalazine, leflunomide, minocycline,
and/or hydroxychloroquine. Patients in this group (n =
10) showed an apparent decrease in DAS28 score of
approximately 50% (to 1.7 to 3.4) after taking DMARDs
(Figure 4B). Importantly, high levels of soluble IL-34
(6.573 ± 2.003 ng/ml) were detected in plasma from RA
patients before DMARDs treatment (Figure 4C). How-
ever, a significant decrease (P < 0.01) in plasma IL-34
levels was observed after taking DMARDs in this group
(Figure 4C). These data suggest that the plasma level of
IL-34 correlates with the level of inflammation in RA
patients.
Effect of IL-34 on PBMCs migration and subsequent OC
formation
Having shown that RA FLS produce IL-34 (Figure 2A
and 3), we thus questioned whether IL-34 produced by
RA FLS has functional activities to induce chemotactic
migration of OCPs and to subsequently induce osteo-
clastogenesis as a substitute for M-CSF in RANKL-
induced osteoclastogenesis. Human PBMCs as OCPs
[27] in the upper chamber and CM from TNFa-treated
RA FLS or recombinant IL-34 (positive control) in the
lower chamber were incubated. Approximately 7.5 × 105
human PBMCs migrated in the presence of recombinant
IL-34; a similar level of cell migration was observed in
the presence of CM, which contains soluble IL-34
secreted from RA FLS (Figure 5A). However, addition of
a blocking Ab against IL-34 to CM reduced the number
of migrated human mononuclear cells in a dose-depen-
dent manner.
To further assess the effects of IL-34 produced by RA
FLS on RANKL-induced OC differentiation, we cultured
isolated human PBMCs with RANKL in the presence or
absence of M-CSF, IL-34, CM, or an anti-IL-34 Ab for
12 to 14 days. M-CSF plus RANKL treatment induced
OC differentiation (851.5 ± 17.7; Figure 5B). IL-34 or
CM from RA FLS cultures containing IL-34 supported
RANKL-induced OC formation to an extent similar to
that of M-CSF. The addition of anti-IL-34 antibody to
block functional IL-34 in CM (CM + R + IL-34 Ab) sig-
nificantly reduced OC formation (472.4 ± 39; P = 0.042)
(Figure 5C). These data demonstrate that IL-34 secreted
by RA FLS is functionally active enough to stimulate the
chemotactic migration of OCPs and subsequent OC
formation.
Discussion
Although RANKL is absolutely required for OC differ-
entiation in vivo [28,29], several cytokines, including
vascular endothelial growth factor and hepatocyte
growth factor, can be substituted for M-CSF in promot-
ing osteoclastogenesis [30-32]. The inflamed synovium
of RA patients is the major source of overproduction of
cytokines, and these cytokines may contribute to osteo-
clastic activation [33]; thus, understanding the specific
Figure 3 Effect of tumor necrosis factor alpha (TNFa) on the
expression of interleukin-34 (IL-34) and macrophage colony-
stimulating factor (M-CSF) in rheumatoid arthritis (RA)
fibroblast-like synovial cells (FLS). (A) RA FLS were treated with
or without 10 ng/ml TNFa for 24 hours, and M-CSF and IL-34
mRNA levels were determined in cell lysates by quantitative reverse
transcriptase-PCR (qRT-PCR). The relative expression of M-CSF (left)
and IL-34 (right) mRNA after TNFa treatment is presented as fold-
change in gene expression compared to untreated controls (none).
Bars indicate the mean and SD of M-CSF or IL-34 mRNA expression
relative to that of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (*P< 0.05, N.S., not significant, compared to none). (B) Cells
were cultured as described in panel A, and the concentration of M-
CSF (left) or IL-34 (right) in the medium was measured by an
enzyme-linked immunosorbent assay (ELISA). (C) TNFa-mediated
induction of M-CSF (left) or IL-34 (right) protein production was
converted into fold change relative to that of control (none). Bars
indicate the mean and SD of M-CSF or IL-34 protein relative to that
of control (*P < 0.05, N.S., not significant, compared to none). (D)
Nuclear factor kappa B (NF-B) and c-Jun N-terminal kinase (JNK)
dependent IL-34 mRNA expression upon TNFa stimulation in RA
FLS. RA FLS were pretreated with the vehicle (dimethyl sulfoxide, 10
μM), NF-B inhibitor, pyrrolidine dithiocarbamate(10 μM), the JNK
inhibitor, SP600125 (10 μM), the p38 inhibitor, SB203580 (10 μM), or
the extracellular signal-regulated protein kinase (ERK) inhibitor,
PD98059 (10 μM), for 30 minutes and then treated with 10 ng/ml
TNFa for 24 hours. Untreated RA FLS were used as a control (none).
M-CSF and IL-34 mRNA levels were determined in cell lysates by
qRT-PCR. The relative expression of IL-34 mRNA is presented as fold
change in gene expression compared to untreated vehicle controls
(*P < 0.05, N.S., not significant, compared to veh). none, no
treatment; veh, vehicle; SP, SP600125; SB, SB203580; PD, PD98059.
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factors capable of replicating the effect of M-CSF is of
considerable research interest.
Inflammatory cytokines, including IL-1b, IL-17 and
TNFa, are elevated in the SF of RA patients [34] and
are known to stimulate osteoclastogenesis through
induction of M-CSF [35-37]. In this study, we demon-
strated that both IL-34 mRNA and protein expression
were up-regulated by TNFa to a greater extent in RA
FLS than in OA FLS, a pattern distinct from that of M-
CSF expression (Figure 2). Thus, this is the first report
describing the stimulation of IL-34 expression by TNFa
in FLS of RA patients, suggesting that RA FLS are much
more susceptible to the production of IL-34 than M-
CSF in response to TNFa. Further study implies a dis-
crete role of IL-34 in the pathological inflammatory set-
ting of RA.
A recent report demonstrated that TNFa induces IL-
34 mRNA via JNK and NF-B, but not the p38 pathway,
in osteoblasts [38]. NF-B, in particular, is responsible
for TNFa-induced M-CSF expression in primary osteo-
blast cells [39]. In our experiments, TNFa-mediated
induction of IL-34 expression was inhibited by an NF-
B inhibitor, indicating that IL-34 expression is regu-
lated, at least in part, by NF-B. Moreover, JNK inhibi-
tion modestly decreased the elevation of IL-34
expression, indicating that JNK may also be involved in
IL-34 expression in FLS of RA patients (Figure 3D).
Several combinations of DMARDs used for the treat-
ment of arthritis conditions [40], such as RA or psoriatic
arthritis (PsA), have been demonstrated to abrogate
inflammation [41]. IL-34 was detected in plasma sam-
ples of RA patients and it was effectively reduced by
DMARDs treatment in RA patients (Figure 4A). Our
data provide an initial indication of the importance of
the clinical correlation between plasma IL-34 levels and
inflammatory responses in RA patients, suggesting the
significance of IL-34 as a plasma factor in RA patients
representing inflammatory arthritis in the pathogenesis
of RA. In our study population, individual variations in
combination therapy were not controlled; thus, addi-
tional clinical studies with a larger number of patients
divided into subgroups is needed to validate the clinical
implications of elevated IL-34 in the pathogenesis of RA.
IL-34, like M-CSF, has been shown to promote osteo-
clastogenesis in combination with RANKL [14,18] and
induce bone resorption activity [18]. We also found that
IL-34 produced from TNFa-stimulated RA-FLS pro-
moted chemotactic migration of human PBMCs and
RANKL-induced osteoclastogenesis (Figure 5), demon-
strating a biologically active function of IL-34. There-
fore, TNFa-stimulated up-regulation of IL-34 in RA FLS
may play a pathological role in RA, possibly at the site
of inflammatory erosive bone resorption and local bone
destruction. In PsA, an inflammatory joint disease char-
acterized by extensive bone resorption, OCPs arise from
TNFa-activated PBMCs that migrate to the inflamed
synovium and subchondral bone, where they are
exposed to unopposed RANKL and TNFa [42]. This
leads to osteoclastogenesis at the erosion front and in
subchondral bone, resulting in a bidirectional assault on
psoriatic bone [42]. A recent report showed that M-CSF
levels are not elevated in SF from patients with PsA to
the same extent as in RA patients [12]. Accordingly, IL-
34 may replace this M-CSF function and contribute to
the pathogenesis of PsA; however, the role of IL-34 in
PsA remains to be investigated.
Genetic ablation of M-CSF in op/op (M-CSF-deficient)
mice and inhibition of M-CSF by administration of anti-
M-CSF mAbs exerts protective effects in a number of
inflammatory and/or autoimmune conditions [43,44].
Moreover, blocking c-Fms inhibits macrophage infiltra-
tion, TNFa production by macrophages, and OC
Figure 4 Correlation between interleukin-34 (IL-34) levels and inflammation in rheumatoid arthritis (RA) patients. (A) IL-34 levels were
determined in plasma of healthy controls (normal), OA or RA patients by n enzyme-linked immunosorbent assay (ELISA) (*P < 0.05, N.S., not
significant, compared to normal). (B) and (C) Plasma was collected from individual RA patients (n = 10) and the same patients were
administrated disease-modifying anti-rheumatic drugs (DMARDs) and followed-up for 1 year. Disease Activity Score 28 (DAS28) activity (A) and IL-
34 levels (ELISA) (B) were determined for each patient in plasma samples collected before and after administration of DMARDs. Symbols indicate
individual data points; horizontal bars show group means (P < 0.01, after versus before DMARDs administration).
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formation and activation in several mouse arthritis mod-
els [12,45], and reduces TNFa-induced inflammatory
arthritis [11], suggesting a therapeutic benefit in RA
treatment. The increase in IL-34 in RA reported here
supports the concept that IL-34 regulates OCP migra-
tion and subsequent OC differentiation, suggesting the
possibility that IL-34 can functionally substitute for M-
CSF and is involved in the RA disease process elicited
by TNFa. It is important to note in this context that
elevated IL-34 in RA SF can activate c-Fms, even in the
absence of M-CSF. Thus, inhibiting c-Fms may be a
more promising strategy than targeting M-CSF in the
treatment of RA where the disease pathogenesis involves
TNFa.
Conclusions
We propose that IL-34 is elevated in RA SF and is pro-
duced by RA FLS. IL-34 expression is enhanced by
TNFa through the NF-B and JNK pathway and is a
biologically active stimulator of OC differentiation that
exerts synergistic effects with RANKL. Further investiga-
tions to define the pathological implications of this cyto-
kine in osteolysis in vivo are warranted.
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Additional file 1: Characteristics of patients with rheumatoid
arthritis (RA). All patients were 30 years or older at the time of RA
diagnosis and their mean ± SD age was 53.3 ± 16.0 years. All patients
were positive for rheumatoid factor (RF) and anti-cyclic citrullinated
peptide (CCP) antibody and had a diagnosis of RA with a median
baseline Disease Activity Score 28 (DAS28) of 5.27 (range 2.9 to 7.4), a
median 1 year DAS28 of 2.58 (1.7 to 3.4), a baseline median erythrocyte
sedimentation rate of 69.6 (28 to 120), and a median baseline C-reactive
protein (CRP) of 1.05 (0.1 to 2.04). With regard to medications used for
the treatment of RA, patients were treated with prednisolone and
disease-modifying antirheumatic drugs (DMARDs) including
methotrexate, sulfasalazine, leflunomide, FK506, and/or
hydroxychloroquine. SD, standard deviation.
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